Denosumab is a monoclonal antibody that inhibits RANKL, a protein essential for the formation and function of bone-resorbing cells called osteoclasts. By potently suppressing bone breakdown, it significantly increases bone mineral density and reduces the risk of fractures. Its primary healthspan relevance is the prevention of osteoporosis and fragility fractures, a major cause of morbidity, mortality, and loss of independence in older adults.
Verdict
Highly effective for bone health, but requires a long-term commitment.
HEALTHSPAN IMPACT
High Value
RISK LEVEL
High
EVIDENCE GRADE
A
MONTHLY COST
$250 - $500
Protocol
- A 60 mg subcutaneous injection administered once every 6 months by a healthcare professional.
Flags
- Discontinuation causes a rapid rebound in bone resorption and a significant increase in fracture risk.
- Requires adequate calcium and vitamin D supplementation to prevent hypocalcemia.
- Rare but serious risks include osteonecrosis of the jaw (ONJ) and atypical femoral fractures.
- May increase the risk of certain infections, particularly skin infections like cellulitis.
- Primarily indicated for individuals with diagnosed osteoporosis or high fracture risk, not general prevention.